Home » Stocks » Lantern Pharma

Lantern Pharma, Inc. (LTRN)

Stock Price: $16.47 USD -0.35 (-2.08%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 102.40M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 6.22M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 18, 2020
Last Price $16.47
Previous Close $16.82
Change ($) -0.35
Change (%) -2.08%
Day's Open 16.82
Day's Range 16.10 - 17.49
Day's Volume 85,245
52-Week Range 10.40 - 19.50

More Stats

Market Cap 102.40M
Enterprise Value 78.82M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 6.22M
Float 2.29M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3,161
Short Ratio 0.43
Short % of Float 0.92%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.74
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 23.59M
Net Cash / Share 3.79
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(48.76% upside)
Current: $16.47
Target: 24.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-2.43-1.73
Net Income-2.43-1.73
Shares Outstanding1.141.11
Earnings Per Share-2.14-1.56
Operating Cash Flow-2.13-1.27
Capital Expenditures-0.010.01
Free Cash Flow-2.13-1.27
Cash & Equivalents1.230.45
Net Cash / Debt1.230.45
Book Value0.94-0.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Lantern Pharma, Inc.
Country United States
Employees 4
CEO Panna L. Sharma

Stock Information

Ticker Symbol LTRN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LTRN
IPO Date June 11, 2020


Lantern Pharma Inc., a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas. Address: 1920 McKinney Avenue, Dallas, TX, United States, 75201